Fourth quarter and full-year 2012 vascular sales increased 14% and 15%, respectively, over the prior year periods. These increases were primarily attributable to growth in the underlying market and market share gains. Additionally, vascular revenue for the year included $6.6 million from sales of medical devices that were developed under the Greatbatch name compared to $4.5 million for 2011, an increase of 47%.In comparison to the prior year, orthopaedic sales for the fourth quarter of 2012 declined 2% (0% constant currency) and 13% (8% constant currency) for the full-year. Foreign currency exchange rate fluctuations decreased orthopaedic revenue by approximately $0.6 million in the fourth quarter of 2012 and $6 million for the year. The remaining decline in 2012 orthopaedic sales was a result of fewer customer product launches and development opportunities due to operational issues within our orthopaedic business, which are aggressively being addressed. In comparison to the sequential third quarter, orthopaedic revenue increased 14% primarily due to the seasonal facility shut-downs in our European operations.
Greatbatch, Inc. Reports 2012 Fourth Quarter And Full Year Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts